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Abstract
Background: Previous studies have documented the high costs of non-dialysis dependent chronic kidney disease
(CKD) but out-of-pocket healthcare expenditures remain poorly explored. This study described total direct and
out-of-pocket expenditures for adults with non-dialysis dependent CKD and compared expenditures with those for
cancer or stroke.
Methods: This study used data from the 2011–2013 Medical Expenditure Panel Survey, a national survey of healthcare
expenditures in the U.S. population. Expenditures were determined for adults with the following chronic diseases:
CKD defined by 585 ICD9 codes (n = 52), cancer (colon, breast or bronchus/lung) (n = 870), or stroke (n = 1104). These
represent adults who were aware of their conditions or visited a healthcare provider for the condition during the study
period. Generalized linear models were used to estimate the marginal effects of CKD, cancer or stroke on adjusted
expenditures compared to adults without CKD, cancer or stroke (n = 72,241) while controlling for demographics and
co-morbidities and incorporating the sample weights of the complex survey design.
Results: The mean age for group with CKD, cancer or stroke was 65.5, 66.1, and 68.2 years, respectively, while mean
age for group without CKD, cancer or stroke was 47.8 years. Median values of total direct and out of pocket healthcare
expenditures ranged from as high as $12,877 (Interquartile Range [IQR] $5031-$19,710) and $1439 ($688–$2732),
respectively, with CKD, to as low as $1189 (IQR $196-$4388) and $226 (IQR $20-$764) in the group without CKD,
cancer or stroke. After adjusting for demographics and comorbidities, the adjusted difference in total direct healthcare
expenditures was $4746 (95% CI $1775-$7718) for CKD, $8608 (95% CI $6167-$11,049) for cancer and $5992 (95% CI
$4208-$7775) for stroke vs. group without CKD, cancer or stroke. Adjusted difference in out-of-pocket healthcare
expenditures was highest for adults with CKD ($760; 95% CI 0-$1745) and was larger than difference noted for cancer
($419; 95% CI 158–679) or stroke ($246; 95% CI 87–406) relative to group without CKD, cancer or stroke.
Conclusions: Total and out of pocket health expenditures for adults with non-dialysis dependent CKD are high and
may be equal to or higher than expenditures incurred by adults with cancer or stroke.
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Background
More than 20 million people or approximately 10% of
U.S. adults currently have non-dialysis dependent chronic
kidney disease (CKD), [1, 2] and almost one out of every
two adults aged 30–64 years is expected to develop CKD
during their lifetime [3, 4]. While dialysis dependent CKD
accounts for only 0.5% of the U.S. population, fee-for ser-
vice expenditures for Medicare beneficiaries with dialysis
dependent CKD exceeded 30 billion dollars in 2013, or
over 7% of Medicare paid claims cost [5]. Nevertheless, an
escalation in healthcare expenditures associated with CKD
starts prior to requirement for dialysis and treatment costs
escalate as non-dialysis dependent CKD progresses [6–8].
The escalation in costs in CKD is largely due to the
increasing burden of comorbidities as CKD progresses
[6, 9–12], thus requiring patients with CKD to seek care
from multiple providers, with an average of 10.8 phys-
ician visits per year [13]. Only cancer patients had a
higher average number of annual physician visits [14].
The total number of medications among adults with
CKD may also be higher than most other chronic med-
ical conditions with one study reporting that over 60%
of adults with stage 3 CKD taking 5 or more different
medications daily [11]. The high total number of phys-
ician visits and medications required for CKD care
drives up total direct healthcare expenditures and likely
also increases out-of-pocket expenditures, creating a
financial burden for patients.
While total expenditures for dialysis dependent and
non-dialysis dependent CKD have been previously docu-
mented, [5, 6, 15, 16] out of pocket costs for non-dialysis
dependent CKD remain poorly explored. Higher out-of-
pocket cost burden can impede efforts to prevent disease
progression. Previous research has shown that some pa-
tients opt to not fill prescriptions or take less than the pre-
scribed amount due to out of pocket costs [17]. The aim
of this study was to describe the total healthcare expendi-
tures including out-of-pocket costs for non-dialysis
dependent CKD and compare these expenditures with
those incurred for cancer and stroke in the U.S. adult
population. We selected these chronic conditions because
both stroke and CKD are the costliest conditions for Part
A Medicare beneficiaries, while for Part B Medicare bene-
ficiaries, cancer and CKD are the costliest conditions [18].
We hypothesized that both direct and out-of-pocket
healthcare expenditures in adults with non-dialysis
dependent CKD are comparable if not higher than expen-
ditures incurred for cancer or stroke.
Methods
Study population
This cross-sectional study described total and out-of-
pocket health care expenditures for the chronic condi-
tions: nondialysis dependent CKD, cancer, and stroke,
each condition exclusively, and compared the expendi-
tures for these chronic conditions with those incurred
among the population without CKD, cancer or stroke.
The study was approved by the Loyola University
Medical Center Institutional Review Board. Data were
obtained from the household, medical conditions and
medical provider component (MPC) files of the Medical
Expenditures Panel Survey (MEPS) for years 2011 to
2013. MEPS is a household survey of the noninstitution-
alized civilian population and is conducted annually. The
household component provides information on respon-
dents’ health status, demographic and socioeconomic
characteristics, employment, access to care, and satisfac-
tion with health care. For the MPC, a sample of medical
providers are contacted to obtain information that
household respondents can not accurately provide about
dates of visits, diagnosis and procedure codes, charges
and payments. The MEPS data are weighted to produce
estimates of healthcare expenditures that are representa-
tive of the non-institutionalized civilian population.
The medical conditions file contains information
describing current medical conditions reported by re-
spondents during participant interviews. Information
that cannot be accurately provided by participants is
collected through telephone calls to providers. A current
condition is defined as a condition linked to an event or
disability day as well as any condition(s) the person is
currently experiencing. These conditions are recorded
by the interviewer as verbatim text and then translated
into International Classification of Diseases, 9th Edition,
Clinical Modification (ICD-9-CM) codes by professional
coders. To preserve confidentiality, nearly all of the diag-
nosis condition codes provided on this file have been
collapsed to 3-digit code categories. MEPS data provide
clinical classification codes (CCC) that are clinically
meaningful categories that group similar conditions and
are detailed in Table 1. Dialysis utilization during a given
year is also collected and classified as a medical event
code. Respondents reported a specific condition as being
bothersome during the study period or as the reason for
a medical event (hospital stay, outpatient visit, emer-
gency room visit, home health episode, prescribed medi-
cation purchase, or medical provider visit). Therefore
conditions that are undiagnosed, not bothersome during
the study period, or not linked with a medical event are
not ascertained in MEPS.
Respondents younger than 21 years were excluded from
this study. A total of 74,452 adults aged 21 years and older
participated in the MEPS study during 2011–2013. Partici-
pants were further excluded if they had received dialysis
or reported more than one of the studied conditions CKD,
cancer and stroke simultaneously. Our study include a
total of 52 sampled persons with non-dialysis dependent
CKD. A total of 1104 sampled persons had CCS codes
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indicating stroke and 870 participants had CCS codes in-
dicating colon, breast or bronchus/lung cancers (Table 1).
Sampled persons without CKD, stroke or cancer totaled
72,241.
Healthcare expenditures
Per-capita annual total direct health care expenditures,
defined as third party (Medicare, Medicaid, private,
other) and patient out-of-pocket payments for medical
services were calculated. Types of medical services in-
cluded inpatient, outpatient, prescription drug, dental,
vision, home health, and payments for other medical
equipment and services reported during the calendar
years 2011–2013. Expenditure values were all calculated
as year 2013 dollars. Out-of-pocket spending included
self-reported payments for coinsurance and deductibles,
and cash outlays for services, supplies, and other items
not covered by health insurance. Out-of-pocket expendi-
tures burden was calculated as the ratio of out-of-pocket
spending to personal income and expressed as a percent-
age varying from 0 to 100 with high out-of-pocket
spending burden as spending 10% or more of personal
income on health care [19].
Covariates
The panel of this study is composed of five rounds of in-
terviews covering two full calendar years. Demographic
questions were asked during each round of interview.
Demographic variables including age, height and weight
and race/ethnicity were self-reported and collected by
MEPS. For this study, race/ethnicity was categorized as
non-Hispanic White, non-Hispanic Black, Hispanic and
other. Health insurance was categorized as public, pri-
vate or none. Body mass index (BMI) was calculated as
weight (kg) divided by height in m (squared). MEPS col-
lected data on total family income and family size and
five categories of poverty status were then defined by
MEPS based on the ratio of family income to family size
and composition: poor (less than 100% to the poverty
line), near poor (100%-125% of the poverty line), low in-
come (125%-less than 200% of the poverty line), middle
income (200%- less than 400% of the poverty line) and
high income (≥400% of the poverty line). Self-reported
perceived mental and physical health statuses were
ascertained in MEPS and categorized as excellent, very
good, good, fair and poor. The presence of other co-
occurring physical conditions were measured as binary
variables based on self-reporting a physician diagnosis of
angina, arthritis, asthma, coronary heart disease, high
cholesterol, diabetes, emphysema, high blood pressure,
heart attack, and other heart disease.
Statistical analysis
All analyses accounted for the complex sampling design
of MEPS dataset by using the sampling weight, variance
estimation stratum and primary sampling unit. The
Taylor-series approach was implemented to estimate
standard errors for weighted survey estimates. Demo-
graphic characteristics, presence of other co-occurring
physical conditions, total health care expenditures, out-
of-pocket spending, and out-of-pocket spending burden
was presented by condition categories using descriptive
statistics. In this study, none of the participants with
non-dialysis dependent CKD and a relatively small
number of participants with cancer or stroke, had zero
expenditures. Therefore the generalized linear model
(glm) was used to estimate the adjusted total health care
expenditures and out-of-pocket spending by the three
condition categories compared to the group without
CKD, cancer or stroke while simultaneously controlling
for race/ethnicity, age, health insurance, gender, poverty
status and presence of other co-occurring physical con-
ditions.. We used the gamma distribution with log-link
function and presented the marginal effects and their
standard errors [20, 21]. The regression analyses did not
adjust for perceived physical and mental health status
and BMI due to the potential collinearity of these
variables with the condition categories and other co-
Table 1 Definition of the clinical classification software (CCS) diagnosis categories in the Medical Expenditure Panel Survey
CCS diagnosis categories ICD-9-CM diagnosis codes Definition
aChronic Kidney Disease (CKD)
158 585, 5853, 5854, 5855, 5856, 5859 CKD
Cancer
14 1530 1531 1532 1533 1534 1535 1536 1537 1538 1539 1590 2303 V1005 Colon Cancer
24 1740 1741 1742 1743 1744 1745 1746 1748 1749 1750 1759 2330 V103 Breast Cancer
19 1622 1623 1624 1625 1628 1629 2312 V1011 Lung Cancer
Stroke
109 430 431 4320 4321 4329 43301 43311 43321 43331 43381 43391 4340 43400
43401 4341 43410 43411 4349 43490 43491 436
Acute cerebrovascular disease
112 4350 4351 4352 4353 4358 4359 Transient cerebral ischemia
aPersons receiving dialysis were excluded
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occurring physical conditions. All analyses were con-
ducted using Stata 13 and P < 0.05 was considered statis-
tically significant.
Results
Table 2 demonstrates characteristics of the populations
with the indicated conditions. The average age in groups
with CKD, cancer, or stroke were 65.5, 66.1, and
68.2 years, respectively. Mean age in group without can-
cer, stroke or CKD was 47.8 years. Private insurance
ranged from as low as 50.3% in the group with stroke to
65.2% in the group with CKD. Only 18.8% of the group
with CKD rated their physical health as excellent or very
good. In contrast, 39.7% and 25.0% of those with cancer
and stroke, respectively, rated their physical health as ex-
cellent or very good. Table 3 demonstrates the preva-
lence of comorbidities in the three chronic condition
groups, exclusively. Of the indicated conditions, the
group with CKD had the highest prevalence of high
cholesterol (85.0%), high blood pressure (87.8%) and dia-
betes (49.6%).
The annual mean total healthcare expenditures ranged
from as high as $12,877 for non-dialysis dependent CKD
to as low as $7428 for the chronic condition cancer
(Table 4). The annual mean out-of-pocket expenditures
was also highest for the group with non-dialysis
dependent CKD ($1439; IQR $688-$2732), and lowest
for the group with stroke ($748; IQR $242–$1559). Fig. 1
shows the out-of-pocket health care expenditure burden,
calculated as the ratio of out-of-pocket spending to per-
sonal income. The annual out-of-pocket health care ex-
penditure burden for cancer and stroke were 5.1 and 5.8,
respectively. However, the out-of-pocket healthcare ex-
penditure burden for group with non-dialysis dependent
Table 2 Demographic and clinical characteristics of U.S. adults aged 21 years or older by condition categories, years 2011-2013
Chronic Kidney Disease (CKD)a Cancerb Stroke No CKD, cancer or strokec
Study sample, n = 74,267 52 870 1104 72,241
Study population estimate over 3 year period, N = 940,337,592 607,506 9,206,890 10,520,699 650,226,082
Age (years) 65.5 66.1 68.2 47.8
Race
Non-Hispanic White (%) 79.7 79.0 73.0 66.4
Non-Hispanic Black (%) 11.6 10.0 15.2 11.2
Hispanic (%) 7.4 8.0 7.8 14.8
Other (%) 1.3 3.0 4.0 7.6
Male (%) 48.7 15.8 49.1 48.5
BMI [kg/m (squared)] 28.3 26.7 26.9 27.1
Poverty Statusd
Poor (%) 9.3 10.9 19.5 12.1
Near Poor (%) 2.6 7.0 7.3 4.4
Low Income (%) 17.2 15.4 19.0 13.6
Middle Income (%) 32.8 30.6 30.4 30.3
High Income (%) 38.1 36.1 23.8 39.7
Health Insurance
Public (%) 26.8 32.9 46.5 17.0
Private (%) 65.2 65.1 50.3 67.7
None (%) 8.1 2.0 3.2 15.4
Perceived Physical Health
Excellent (%) 6.0 13.0 4.2 24.7
Very Good (%) 12.8 26.7 20.8 34.1
Good (%) 33.0 29.0 29.3 28.3
Fair (%) 35.3 16.8 25.6 9.6
Poor (%) 10.3 11.7 17.6 2.9
aExcludes dialysis patients
bIncludes breast, colon & lung cancers
cExcludes CKD, cancer and/or stroke. The condition categories are mutually exclusive
dBased on the ratio of family income to family size and composition: poor = less than 100% to the poverty line, near poor =100%-125% of the poverty line, low
income =125%-less than 200% of the poverty line, middle income =200%- less than 400% of the poverty line, and high income = ≥ 400% of the poverty line
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CKD was 7.2, comparatively higher than the annual out-
of-pocket health care expenditure burden for the other
groups.
After adjusting for demographic variables and comor-
bidities, CKD, cancer and stroke were associated with
significantly higher direct and out-of-pocket expendi-
tures compared to the population without CKD, cancer
or stroke. The highest difference in direct expenditures
was noted in the group with cancer with $8608 (95% CI
$6167-$11,049) higher total direct healthcare expendi-
tures relative to population without CKD, cancer or
stroke after adjustment for demographics and co-
morbidities. The highest difference in out-of-pocket ex-
penditures was noted in the group with CKD with $760
(95% CI 0-$1745) higher out-of-pocket spending relative
to population without CKD, cancer or stroke after ad-
justment for demographics and co-morbidities (Table 5).
In contrast, stroke was associated with $5992 (95% CI
$4208-$7775) higher total direct healthcare expenditures
and $246 (95% CI $87-$406) higher out-of-pocket ex-
penditures relative to the group without CKD, cancer or
stroke (Table 5).
Discussion
This study showed that adults with diagnosed non-
dialysis dependent CKD based on 585 ICD9 codes had
higher total direct and higher out-of-pocket healthcare
expenditures compared to adults with stroke or cancer.
Our analyses included adults from all stages of CKD in-
cluding early, moderate, and advanced stages, who were
aware of their condition or actively seeking treatment.
We chose to compare non-dialysis dependent CKD
healthcare expenditures with those for cancer and stroke
due to the fact that these chronic conditions are among
the most common, costly, and preventable chronic con-
ditions in the U.S [18]. The adjusted out-of-pocket cost
burden for the group with CKD was substantially higher
compared to the out-of-pocket cost burden for adults
without CKD, cancer or stroke.
Our findings were similar to a previous study that ex-
amined the annual total expenditures for year 2011 for
patients with both CKD and diabetes [15]. However,
CKD ascertainment was different between the two stud-
ies. In our study, we used the MPC files and associated
ICD9 codes to define current conditions including the
presence of CKD. In the Ozieh et al. article [15], respon-
dents were identified as having CKD if they responded
yes to the question “Has diabetes caused kidney prob-
lems?”, while diabetes was ascertained by answering yes
to the question: “Have you ever been told by a doctor or
health professional that you had diabetes?”
Progression of non-dialysis CKD is known to be asso-
ciated with escalating healthcare costs [6, 8, 22]. In an a
analysis of 83,705 adults with type 2 diabetes enrolled in
a Medicare Advantage plan, Stage 4 CKD was associated
with an incremental cost increase of $33,131 relative to
stage 1 or no CKD in the 98th percentile of total costs
[22]. In a study of Medicare enrollees, CKD was esti-
mated to increase the average Medicare payment for
part A by a factor of 12.1 and for part B by a factor of
Table 3 Prevalence of comorbidities among U.S. adults aged 21years or older by conditions, years 2011-2013
Comorbidity CKDa Cancerb Stroke No CKD, cancer or strokec
Angina (%) 10.3 5.9 12.6 2.3
Arthritis (%) 63.7 55.2 61.2 25.8
Asthma (%) 11.8 14.7 11.8 9.3
Coronary Heart Disease (%) 20.8 12.7 26.6 5.3
High Cholesterol (%) 85.0 56.2 66.8 31.5
Diabetes (%) 49.6 19.3 31.2 9.3
Emphysema (%) 1.2 10.7 7.8 2.0
High Blood Pressure (%) 87.8 60.9 78.2 33.8
Heart Attack (%) 4.9 8.9 22.6 3.5
Other Heart Disease (%) 41.5 24.3 34.4 10.7
aExcludes dialysis patients
bIncludes breast, colon & lung cancers
cExcludes CKD, cancer and/or stroke. The condition categories are mutually exclusive
Table 4 Annual total direct and out-of-pocket healthcare
expenditures (in $2013 US) of U.S. adults aged 21years or older





Median (IQR) Median (IQR)
CKDa 12,877 (5031 – 19,710) 1439 (688 – 2732)
Cancerb 7428 (3460 – 18,323) 770 (349– 1703)
Stroke 8150 (3966– 19,375) 748 (242 – 1599)
Population without CKD,
cancer or strokec
$1189 (196 – 4388) 226 (20 – 764)
aExcludes dialysis patients; CKD, Chronic kidney disease
bIncludes breast, colon & lung
cExcludes CKD, cancer and/or stroke. Condition categories are mutually exclusive
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4.4 among men. Somewhat lower estimates were noted
for female enrollees [18]. However, individuals receiving
dialysis were not excluded. Previous studies did not
examine out of pocket expenditures and associated out
of pocket burden. Our study suggests that out of pocket
healthcare expenditures for adults with non-dialysis
dependent CKD may be higher than those for adults
with cancer or stroke and lead to a higher financial
burden for individual patients. These findings add to a
growing body of literature that confirms the strong
financial burden of healthcare costs for patients with
CKD. The higher costs for CKD also hold public health
significance because prevalence of CKD is increasing
among Medicare Part A beneficiaries, while prevalence
of stroke and many cancers are decreasing [9].
The unadjusted higher total healthcare expenditures
for CKD may be due to the higher number of co-
morbidities in this group. The group with CKD defined
by 585 ICD9 codes had the highest prevalence of high
cholesterol, diabetes, and high blood pressure. Higher
number of co-morbidities is associated with higher
number of physician visits and medications utilized as
Fig. 1 Mean out-of-pocket health care expenditures burden of U.S. adults aged 21 years or older by condition categories, years 2011–2013
Table 5 Adjusted differences in total direct and out-of-pocket health care expenditures (in $2013 US) of U.S. adults aged 21years or
older by conditions, years 2011-2013
dDifferences in total direct healthcare expenditures ($) dDifferences in out-of-pocket expenditures ($)
No CKD, cancer or strokec Referent 95% CI P-value Referent 95% CI P-value
CKDa $4746 $1775–$7718 0.002 $760 0–1745 0.130
Cancerb $8608 $6167–$11,049 <0.001 $419 $158–$679 0.002
Stroke $5992 $4208–$7775 <0.001 $246 $87–$406 0.002
aExcludes dialysis patients; CKD, chronic kidney disease
bIncludes breast, colon & lung
cExcludes CKD, cancer and/or stroke. The condition categories are mutually exclusive
dAnalysis compares expenditure per chronic condition category, adjusted for the variables listed and race/ethnicity, age, health insurance, gender, poverty status
and presence of other co-occurring physical conditions and all costs were inflated to 2013 dollars
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documented in previous studies [8, 11, 15]. In fact, the ma-
jority of adults with moderate to severe CKD may have 3
or more co-morbid conditions and take at least 5 medica-
tions [11]. The unadjusted median total and out-of-pocket
healthcare expenditures of respondents with CKD were
substantially larger than expenditures for respondents with
cancer and stroke. However, total direct healthcare expen-
ditures decreased and became more comparable to those
for stroke and cancer after adjusting for demographic vari-
ables and comorbidities. The out-of-pocket expenditures
remained higher in the CKD group.
Results from our study are generalizable to adults who
are aware of their conditions or who visited a healthcare
provider for the condition during the study period. Our
CKD sample is therefore, not representative of all U.S.
adults with CKD, because the majority with CKD remain
unaware of their condition [23].
The strengths of this study included the use of a nation-
ally representative survey of U.S. healthcare expenditures
and MEPS data are weighted so that expenditure estimates
for a given condition reflect expenditures for the total U.S.
population with that condition. However, as noted earlier,
presence of conditions in MEPS are based on self-report
and rely on accurate recollection by respondents. Also, re-
cords in the MEPS Conditions File correspond to current
conditions; meaning, the respondent reported the condi-
tion as the reason for a particular medical event such as an
outpatient visit, the reason for one or more episodes of dis-
ability days, or ‘bothering’ the person during the reference
period., The number of sampled persons with non-dialysis
dependent CKD with 585 ICD9 codes was small and confi-
dence intervals for the healthcare expenditure estimates
were wider than the estimates for the other conditions.
Therefore, results from our study should be interpreted in
light of the small number of respondents with non-dialysis
dependent CKD included in the analyses. The MEPS is
representative of the U.S. population and our findings may
not be generalizable to non-U.S. populations. Differences
in out-of-pocket expenditures for this group relative to the
group without CKD, cancer or stroke included zero, which
may have been due to the small sample size. Because many
adults with CKD remain unaware of their condition, the
results from this study do not reflect healthcare expendi-
tures for all U.S. adults with CKD.
Conclusions
In conclusion, our findings in adults with diagnosed CKD
showed that CKD was associated with both high total and
out of pocket healthcare expenditures in the U.S. and
these expenditures were similar to those of other costly
chronic diseases, namely cancer and stroke. Future re-
search should examine interventions for preventing the
onset or progression of CKD and reducing the out-of-
pocket expenditure burden for adults with CKD.
Additional file
Additional file 1: Relevant Stata commands used in the study available
in a Stata commands ‘do’ file. (DO 12 kb)
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download_data_files.jsp.
Stata 13 (College Statin, Texas) was used to conduct the analyses; we used
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(log)] and the [margins, dydx (*)] commands to estimate adjusted total
health care expenditures and out-of-pocket spending by the three condition
categories compared to the group without CKD, cancer or stroke while
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i.arthritis i.asthma i.coronaryheart i.highcholesterol i.diabetes i.emphysema
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Other relevant Stata commands are provided in Additional file 1.
Authors’ contributions
All the authors made substantive intellectual contributions in this study. CS, HK,
and TM made substantial contributions to conception and design, acquisition
of data, analysis and interpretation of data, drafting the manuscript and revising
it critically for important intellectual content. KG, KV, DL, VB made substantial
contributions to interpretation of data and revising it critically for important
intellectual content. All the authors have given final approval of the version to
be published and they have participated sufficiently in the work to take public
responsibility for appropriate portions of the content.
Competing interests
KG has lab funding with Complexa Company but no other financial or
non-financial competing interests. The other authors declare that they have
no financial or non-financial competing interests.
Data from this study was presented at AcademyHealth/Agency for
Healthcare Research and Quality (AHRQ) Annual Conference, Crystal City,
Virginia on October 2015 and at the American Society of Nephrology
meeting, November 2015, San Diego, CA.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The Loyola University Medical Center Institutional Review Board approved
the study, which used publicly available data from the Agency for Healthcare
Small et al. BMC Nephrology  (2017) 18:3 Page 7 of 8
Research and Quality’s (AHRQ) Medical Expenditure Panel Survey (MEPS).
All information for MEPS is collected with assurances of confidentiality, and
individual identifiers have been removed from the micro data contained in
these files. Nevertheless, by using these data, the authors signified their
agreement to comply with the MEPS data use agreement. Therefore,
consent to participate was not collected by the authors in this study. The




1Department of Public Health Sciences, Loyola University Chicago, 2160 S.
First Ave, Maywood, IL 60153, USA. 2Division of Nephrology and
Hypertension, Loyola University Medical Center, Maywood, IL, USA. 3Hines
Veterans Affairs Medical Center, Hines, IL, USA.
Received: 25 August 2016 Accepted: 21 December 2016
References
1. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro 3rd AF, Feldman HI,
Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic
Kidney Disease Epidemiology Collaboration). A new equation to estimate
glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.
2. Murray CJ, Atkinson C, Bhalla K, Birbeck G, Burstein R, Chou D, Dellavalle R,
Danaei G, Ezzati M, Fahimi A, Flaxman D, Foreman, Gabriel S, Gakidou E,
Kassebaum N, Khatibzadeh S, Lim S, Lipshultz SE, London S, Lopez, MacIntyre MF,
Mokdad AH, Moran A, Moran AE, Mozaffarian D, Murphy T, Naghavi M, Pope C,
Roberts T, Salomon J, Schwebel DC, Shahraz S, Sleet DA, Murray, Abraham J,
Ali MK, Atkinson C, Bartels DH, Bhalla K, Birbeck G, Burstein R, Chen H,
Criqui MH, Dahodwala, Jarlais, Ding EL, Dorsey ER, Ebel BE, Ezzati M,
Fahami, Flaxman S, Flaxman AD, Gonzalez-Medina D, Grant B, Hagan H,
Hoffman H, Kassebaum N, Khatibzadeh S, Leasher JL, Lin J, Lipshultz SE,
Lozano R, Lu Y, Mallinger L, McDermott MM, Micha R, Miller TR, Mokdad AA,
Mokdad AH, Mozaffarian D, Naghavi M, Narayan KM, Omer SB, Pelizzari PM,
Phillips D, Ranganathan D, Rivara FP, Roberts T, Sampson U, Sanman E,
Sapkota A, Schwebel DC, Sharaz S, Shivakoti R, Singh GM, Singh D, Tavakkoli M,
Towbin JA, Wilkinson JD, Zabetian A, Murray, Abraham J, Ali MK, Alvardo M,
Atkinson C, Baddour LM, Benjamin EJ, Bhalla K, Birbeck G, Bolliger I, Burstein R,
Carnahan E, Chou D, Chugh SS, Cohen A, Colson KE, Cooper LT, Couser W,
Criqui MH, Dabhadkar KC, Dellavalle RP, Jarlais, Dicker D, Dorsey ER, Duber H,
Ebel BE, Engell RE, Ezzati M, Felson DT, Finucane MM, Flaxman S, Flaxman AD,
Fleming T, Foreman, Forouzanfar MH, Freedman G, Freeman MK, Gakidou E,
Gillum RF, Gonzalez-Medina D, Gosselin R, Gutierrez HR, Hagan H,
Havmoeller R, Hoffman H, Jacobsen KH, James SL, Jasrasaria R, Jayarman S,
Johns N, Kassebaum N, Khatibzadeh S, Lan Q, Leasher JL, Lim S, Lipshultz SE,
London S, Lopez, Lozano R, Lu Y, Mallinger L, Meltzer M, Mensah GA,
Michaud C, Miller TR, Mock C, Moffitt TE, Mokdad AA, Mokdad AH, Moran A,
Naghavi M, Narayan KM, Nelson RG, Olives C, Omer SB, Ortblad K, Ostro B,
Pelizzari PM, Phillips D, Raju M, Razavi H, Ritz B, Roberts T, Sacco RL, Salomon J,
Sampson U, Schwebel DC, Shahraz S, Shibuya K, Silberberg D, Singh JA,
Steenland K, Taylor JA, Thurston GD, Vavilala MS, Vos T, Wagner GR,
Weinstock MA, Weisskopf MG, Wulf S, Murray, U.S. Burden of Disease
Collaborators. The state of US health, 1990–2010: burden of diseases, injuries,
and risk factors. JAMA. 2013, 310(6):591–608.
3. Anonymous. Centers for Disease Control and Prevention. Chronic Kidney
Disease Surveillance System-United States. http://www.cdc.gov/ckd.
Accessed 2 July 2016.
4. Grams ME, Chow EK, Segev DL, Coresh J. Lifetime incidence of CKD stages
3–5 in the United States. Am J Kidney Dis. 2013;62(2):245–52.
5. Anonymous. United States Renal Data System Annual Data Report 2014.
Chapter 2: Identification and Care of Patients with Chronic Kidney Disease.
https://www.usrds.org/2014/download/V1_Ch_02_Care-and-ID-of-CKD-
Patients.pdf. Accessed 2 July 2016.
6. Honeycutt AA, Segel JE, Zhuo X, Hoerger TJ, Imai K, Williams D. Medical
costs of CKD in the Medicare population. J Am Soc Nephrol.
2013;24(9):1478–83.
7. Braun L, Sood V, Hogue S, Lieberman B, Copley-Merriman C. High burden
and unmet patient needs in chronic kidney disease. Int J Nephrol Renovasc
Dis. 2012;5:151–63.
8. Wang V, Vilme H, Maciejewski ML, Boulware LE. The economic burden of
chronic kidney disease and end-stage renal disease. Semin Nephrol.
2016;36(4):319–30.
9. Erdem E. Prevalence of chronic conditions among Medicare Part A
beneficiaries in 2008 and 2010: are Medicare beneficiaries getting sicker?
Prev Chronic Dis. 2014;11:130118.
10. Anonymous. Centers for Medicare and Medicaid Services. Chronic
conditions among Medicare beneficiaries, chartbook. Baltimore: U.S.
Department of Health and Human Services; 2012.
11. Fraser S, Roderick P, May C, McIntyre N, Mcintyre C, Fluck R, Shardlow A,
Taal M. The burden of comorbidity in people with chronic kdieny disease
stage 3: A cohort study. BMC Nephrol. 2015;16(1):193.
12. Soni A, Wright J. Average annual health care use and expenditures for
kidney disease among adults 18 and older, U.S. civilian noninstitutionalized
population, 2003–2007. Statistical Brief 306. Rockville: Agency for Health
Care Research and Quality; 2010. http://www.meps.ahrq.gov/mepsweb/
data_files/publications/st306/stat306.pdf. Accessed 2 July 2016.
13. Anonymous. United States Renal Data System Annual Data Report 2013.
Atlas of chronic kidney disease in the United States, National Institutes of
Health, National Institute of Diabetes and Digestive and Kidney Diseases,
Bethesda, MD. 2013.
14. Schneider K, O'Donnell BE, Dean D. Prevalence of multiple chronic
conditions in the United States’ Medicare population. Health Qual Life
Outcomes. 2009;7:82.
15. Ozieh MN, Dismuke CE, Lynch CP, Egede LE. Medical care expenditures
associated with chronic kidney disease in adults with diabetes: United
States 2011. Diabetes Res Clin Pract. 2015;109(1):185–90.
16. Roggeri A, Roggeri DP, Zocchetti C, Bersani M, Conte F, ReNe (Renal Lombardy
Network), Additional contributors from ReNe Network. Healthcare costs of the
progression of chronic kidney disease and different dialysis techniques
estimated through administrative database analysis. J Nephrol. 2016 May 10.
[Epub ahead of print]
17. Kaiser Family Foundation, Kaiser Health Tracking Poll: Public Opinion on
Healthcare Issues. 2009. http://kaiserfamilyfoundation.files.wordpress.com/
2013/01/7891.pdf. Accessed 1 Nov 2016.
18. Erdem E, Prada SI, Haffer SC. Medicare payments: how much do chronic
conditions matter? Medicare Medicaid Res Rev. 2013, 3(2). doi:10.5600/
mmrr.003.02.b02. eCollection 2013.
19. Meraya AM, Raval AD, Sambamoorthi U. Chronic condition combinations
and health care expenditures and out-of-pocket spending burden among
adults, Medical Expenditure Panel Survey, 2009 and 2011. Prev Chronic Dis.
2015;12:E12.
20. Manning WG, Mullahy J. Estimating log models: To transform or not to
transform? J Health Econ. 2001;20(4):461–94.
21. Hardin J, Hilbe J. Generalized linear models and extensions. 2nd ed. College
Station, Texas: Stata Press; 2007.
22. Slabaugh SL, Curtis BH, Clore G, Fu H, Schuster DP. Factors associated with
increased healthcare costs in Medicare Advantage patients with type 2
diabetes enrolled in a large representative health insurance plan in the US.
J Med Econ. 2015;18(2):106–12.
23. Plantinga LC, Boulware LE, Coresh J, Stevens LA, Miller 3rd ER, Saran R,
Messer KL, Levey AS, Powe NR. Patient awareness of chronic kidney disease:
trends and predictors. Arch Intern Med. 2008;168(20):2268–75.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Small et al. BMC Nephrology  (2017) 18:3 Page 8 of 8
